Intranasal GSK2245035, a Toll-like receptor 7 agonist, does not attenuate the allergen-induced asthmatic response in a randomized, double-blind, placebo-controlled experimental medicine study.
<h4>Background</h4>Allergic asthma is a heterogenous disorder predominantly driven by a type 2 inflammatory response to aeroallergens. Therapeutic modulation to rebalance these type 2 responses may offer clinical benefit for allergic respiratory inflammatory diseases, with the potential...
Main Authors: | Hilary Siddall, Diana Quint, Hitesh Pandya, Will Powley, Shaila Shabbir, Jens M Hohlfeld, Dave Singh, Laurie Lee |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0240964 |
Similar Items
-
Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy
by: Max E. Kirtland, et al.
Published: (2020-11-01) -
Clinical and laboratory studies of the fate of intranasal allergen.
by: Janet Rimmer, et al.
Published: (2015-01-01) -
House Dust Mite Allergen Regulates Constitutive Apoptosis of Normal and Asthmatic Neutrophils via Toll-Like Receptor 4.
by: Do Hyung Kim, et al.
Published: (2015-01-01) -
Inhibition of the early asthmatic response to inhaled allergen by the 5-lipoxygenase activating protein inhibitor GSK2190915: a dose–response study
by: Singh D, et al.
Published: (2013-12-01) -
Inflammatory mechanisms in late asthmatic responses to allergen challenge
by: Evans, David John
Published: (1997)